home > news > detailed info

Cherwell launches new support hub for growing Redipor® prepared media distributor network

Cherwell Laboratories

New online resource centre for distributors ensures Redipor customers receive quality support for environmental monitoring applications internationally

Bicester, UK, 6th August 2020: Cherwell Laboratories, specialist suppliers of environmental monitoring and process validation solutions for the pharmaceutical and related industries, has launched a Redipor® prepared media distributor resource centre website. Developing this online knowledge hub supports Cherwell’s growing international distribution network within Europe and now Asia. This means that all Redipor microbiological media customers will receive quality support for their environmental monitoring, sterility testing and process validation applications, whatever their location.

The new Redipor distributor resource centre securely houses lots of useful material, including prepared media product information, safety data sheets, guides and updates which are readily accessible to the distributor at all times. This detailed information in turn enables them to help ensure the controlled environment monitoring efforts of Redipor users run as smoothly as possible. Further supporting in-house expertise, Cherwell invests time in developing a Redipor product champion at each of its distributors; training them in its processes and the complete range of Redipor culture media products, including features, benefits and applications. This is all key to ensuring customers are advised on the right solutions for their needs.

“We are proud that the Redipor range has for many years been associated with quality products supported by an efficient, responsive and truly flexible service for small and large users alike. We therefore take great care in selecting the right partners to work closely with us to supply our products internationally,” said Andy Whittard, Managing Director, Cherwell Laboratories. “Ensuring that all our distributors can also offer quality industry expertise and product support is crucial to us. This is because maintaining cleanrooms and other aseptic areas to the most stringent regulations, plus validating sterility testing processes, not only requires high quality prepared culture media but also quality in customer care.”

Cherwell’s network of expert distributors has been growing in Europe in recent years, now it has also carefully identified partners within Asia who understand the needs of the pharmaceutical and associated industries involved in aseptic processing. Cherwell has recently appointed two new distributors in the region, these are SPD Scientific in Singapore and Trans-Enor in Taiwan. These new distributors, along with ATS Korea in South Korea, are significantly raising the profile of Cherwell’s quality Redipor prepared microbiological media products in Asia. All of Cherwell’s distribution partners can be found on its website.

Redipor prepared culture media products are widely used in pharmaceutical, compounding, hospital pharmacy manufacturing units and other related industries where cleanroom-based manufacturing is required. The Redipor range offers a vast selection of Contact plates and Petri dishes, plus liquid media in a variety of formats. Bespoke culture media options to meet specific needs are also available. Cherwell’s Redipor manufacturing facility is ISO 9001 registered, with all products undergoing stringent quality tests and QC certification. 100% inspection processes, gamma irradiation and special packaging further deliver absolute confidence in product quality.

For more information about Cherwell Laboratories, please visit, follow @CherwellLabs on Twitter or follow us on LinkedIn.
phone 01869 355500
email Launton Business Centre Murdock Rd, Bicester OX26 4XB
Print this page
Send to a friend
News and Press Releases

CPhI Annual Report 2020 Part 1: 2025 will see cell and gene therapy capacity shortages in the USA and 10+ mAb approvals in China

Amsterdam, 16 September 2020: CPhI Annual Report – launched ahead of the first CPhI Festival of Pharma (5-16 October, 2020), the world’s largest digital pharma Expo – predicts dramatic growth of new mAb production in China, capacity shortages for cell and gene therapies in the USA, and the widespread global adoption of single-use technologies, but only limited continuous bioprocessing.
More info >>

White Papers

Conveying Medical Guidance in Clinical Trials – A Survey

Europital Medical Consultancy

With the incremental demand for proactive safety surveillance throughout the conduct of clinical trials, the role of Medical Management is at the fore in ensuring the safety and wellbeing of the participants. The complex responsibilities of a Medical Monitor (MM) starts from the design and development phase, through to study close out. Understanding the principle behind the protocol and the prospective medical solution the study would deliver forms the bloodline for the MM role. Often, the MM is the face of contact for both the site personnel and the study team members with regard to medical, safety and scientific issues within the project. When it comes to medical guidance, the communication channel used to deliver solutions contributes to a large extent in effectively managing decisive situations. Our previous study on acquiring medical guidance from an operations team perspective revealed that e-mails were the most used communication method (see the article, 'Talking Points', in ICT November 2014). In our efforts to further strengthen the mode of medical guidance delivery, we designed a survey to study the existing trend and constraints in this communication chain management, as outlined here.
More info >>

Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement